Amount Raised
$130 Million
Round Type
Post-IPO Equity
BrisbaneBiotechnologyDescription
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $130 million, before deducting placement agent fees and other expenses. The private placement was led by Redmile Group, LLC, with participation by Adage Capital Partners LP, Bain Capital Life Sciences, Driehaus Capital Management, Fairmount, Satter Medical Technology Partners and Venrock Healthcare Capital Partners.
Quick answer
Annexon raised $130 Million in a Post-IPO Equity round, dated July 8, 2022. Annexon is based in Brisbane, California, United States.
- How much did Annexon raise?
- Annexon raised $130 Million in a Post-IPO Equity round on July 8, 2022.
- What does Annexon do?
- Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders..
- Where is Annexon based and how big is it?
- Annexon is based in Brisbane, California, United States. Fundz records about 119 employees.
- Who are the decision-makers at Annexon?
- Fundz holds 1 contact at Annexon, including the Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Annexon that raised within 45 days of this round, from Fundz verified event records.
- Adastra raised an undisclosed amount on August 22, 2022.
- Fennec Pharmaceuticals raised $5M on August 22, 2022.
- Porton Advanced Solutions raised an undisclosed amount (Series B) on August 22, 2022.
- Avelos Therapeutics raised an undisclosed amount (Series A) on August 22, 2022.
- Ubie raised $26M (Series C) on August 22, 2022.
- Rose Therapeutics raised $650K (Seed) on August 22, 2022.
Who to call at Annexon, and when
A new round usually means Annexon is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Annexon raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Annexon, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Annexon. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Annexon raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Annexon raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.